Hepion Pharmaceuticals, Inc.
Liquid biopsy diagnostic platform with methylated DNA and circulating tumor RNA biomarkers for hepatocellular carcinoma detection
- Sector
- Medtech
- Headquarters
- RED BANK, NJ
- Founded
- 2013
- Latest Form D
- $700K, Apr 2026
- Total capital
- $46.8M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $46.8M
- 8 Form D · last Apr 2026
- 6 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 15 pending · first 2025
- Rank in peer group#55 of 160
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 8th filing$700K
- Private capital raisedForm D · SEC · 7th filing$2.9M
- Private capital raisedForm D · SEC · 6th filing$5M
- Private capital raisedForm D · SEC · 5th filing$20M
- Private capital raisedForm D · SEC · 4th filing$1.3M
- Private capital raisedForm D · SEC · 3rd filing$9M
- Private capital raisedForm D · SEC · 2nd filing$4.7M
- Private capital raisedForm D · SEC · 1st filing$3.2M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 160 peers
Line = medianMedtech · Instrument
- Granted patents#55 · top 34%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Anand ReddiDirectorNamed in SEC Form D filings
- Arnold P. LippaDirectorNamed in SEC Form D filings
- Chase LoPrioreDirectorNamed in SEC Form D filings
- Gary S. JacobDirectorNamed in SEC Form D filings
- Gary S. JacobsDirectorNamed in SEC Form D filings
- Gary StetzExecutive Officer, DirectorNamed in SEC Form D filings
Show all 16 people
- John P. BrancaccioDirectorNamed in SEC Form D filings
- John CavanExecutive OfficerNamed in SEC Form D filings
- Kaouthar P. LbiatiDirectorNamed in SEC Form D filings
- Michael P. PurcellDirectorNamed in SEC Form D filings
- Petrus P. WijngaardDirectorNamed in SEC Form D filings
- Robert FosterExecutive Officer, DirectorNamed in SEC Form D filings
- Sireesh AppajosyulaDirectorNamed in SEC Form D filings
- Timothy P. BlockDirectorNamed in SEC Form D filings
- Todd HobbsExecutive OfficerNamed in SEC Form D filings
- Vincent LoPrioreExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 16- GrantedUse Of Cyclosporine Analogues For Treating FibrosisUSPTOUS 12,409,206
- PendingTreating A Disease Using A Pharmaceutically Active Ingredient Present In A Pseudo-ternary Phase SystemUSPTOApplication 18451581
- PendingPseudo-ternary Phase System For Improving Solubility Of A Pharmaceutically Active IngredientUSPTOApplication 18451462
Show all 16 patent records
- Use Of Cyclosporine Analogues For Treating FibrosisSep 9, 2025 · US 12,409,206Granted
- Treating A Disease Using A Pharmaceutically Active Ingredient Present In A Pseudo-ternary Phase SystemFeb 20, 2025 · Application 18451581Pending
- Pseudo-ternary Phase System For Improving Solubility Of A Pharmaceutically Active IngredientDec 14, 2023 · Application 18451462Pending
- Forming A Self-microemulsifying Drug Delivery SystemDec 7, 2023 · Application 18451456Pending
- Generating A Microemulsion Formation With Improved SolubilityDec 7, 2023 · Application 18451467Pending
- Use Of Cyclosporine Analogues As Antithrombotic AgentsJun 2, 2022 · Application 17535692Pending
- Use Of Cyclosporine Analogues For Treating CancerSep 2, 2021 · Application 17184433Pending
- Pharmaceutical Formulations Of Cyclosporine AnalogsMay 28, 2020 · Application 16693051Pending
- Solid State Forms Of RencofilstatApplication PCTUS2024033050Pending
- Use Of Cyclosporine Analogues For Treating FibrosisApplication PCTUS2021018639Pending
- Use Of Cyclosporine Analogues As Antithrombotic AgentsApplication 63118947Pending
- Anti-fibrotic And Anti-cancer Activities Of Cyclosporine Analogue Molecules Modified At Amino Acid 1 And 3Application 62981383Pending
- Treatment Of Fibrotic Diseases In Multiple OrgansApplication 62978526Pending
- Pharmaceutical Formulations Of Cyclosporine AnalogsApplication PCTUS2019062849Pending
- Use Of Cyclosporine Analogues For Treating CancerApplication PCTUS2021019480Pending
- Use Of Cyclosporine Analogues As Antithrombotic AgentsApplication PCTUS2021060885Pending
Related companies, and why
- Tendyne Holdings, Inc.Similar federal contract value in Medtech · null in contracts
- CALCIVIS LTDSimilar federal contract value in Medtech · null in contracts
- Watermark Medical Holdings, Inc.Similar federal contract value in Medtech · null in contracts
- HEARTLUNG CORPORATIONSimilar federal contract value in Medtech · null in contracts
- Spirair, Inc.Similar federal contract value in Medtech · null in contracts
- Opio Connect, Inc.Similar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .